康复新液联合胸腺肽对老年肺结核患者的疗效及免疫功能的影响  

Efficacy of kangfuxin liquid combined with thymosin in treatment of pulmonary tuberculosis and its impact on immune function in elderly patients

作　　者：马军珂 张静[1] 王世岩 崔俊伟[3] Ma Jun-ke;Zhang Jing;Wang Shi-yan;Cui Jun-wei(The First Division,Department of Tuberculosis,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,China;Department of Genetics,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,China;The Second Division,Department of Tuberculosis,First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,China)

机构地区：[1]新乡医学院第一附属医院结核内科一病区,新乡453000 [2]新乡医学院第一附属医院遗传科,新乡453000 [3]新乡医学院第一附属医院结核内科二病区,新乡453000

出　　处：《中国药物应用与监测》2025年第1期43-46,共4页Chinese Journal of Drug Application and Monitoring

基　　金：2023年河南省省级医疗卫生服务能力提升项目(豫财社[2023]68号)。

摘　　要：目的探究康复新液联合胸腺肽对老年肺结核患者的疗效及免疫功能的影响。方法回顾性选取2020年1月至2023年2月在新乡医学院第一附属医院结核内科治疗的老年肺结核患者117例,根据治疗方法分为观察组62例和对照组55例。对照组接受康复新液治疗,观察组接受康复新液联合胸腺肽治疗,持续治疗6个月。比较两组老年肺结核患者的疗效、免疫功能、肺功能以及炎症因子的变化情况。结果治疗6个月后,观察组的总有效率83.87%(52/62)高于对照组64.15%(34/55)(χ^(2)=5.892,P<0.05)。治疗后,两组老年肺结核患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、第1秒用力呼气容积(FEV1)/用力肺活量(FVC)、用力呼气峰值流速(PEF)、FVC、γ-干扰素(IFN-γ)水平均较治疗前升高(均P<0.05),CD8^(+)、CRP、IL-6水平均较治疗前下降(均P<0.05);治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、FEV1/FVC、PEF、FVC、IFN-γ水平均比对照组高[分别为(66.76±3.22)%vs(64.03±3.15)%、(34.02±3.47)%vs(30.02±3.25)%、(1.27±0.29)%vs(1.14±0.22)%、(84.64±10.67)%vs(75.44±10.13)%、(81.28±13.66)pg·mL^(-1)vs(70.13±11.85)pg·mL^(-1)、(3.51±0.68)L vs(2.67±0.62)L、(35.59±3.10)ng·L^(-1)vs(28.43±3.56)ng·L^(-1)](t=4.624、6.411、2.705、4.767、4.687、6.950、11.629,均P<0.05),CD8^(+)、CRP、IL-6水平均低于对照组[分别为(27.67±2.78)%vs(31.18±3.08)%、(11.47±2.31)mg·L^(-1)vs(16.16±2.45)mg·L^(-1)、(23.67±2.35)pg·mL^(-1)vs(29.13±2.44)pg·mL^(-1)](t=6.479、10.653、12.319,均P<0.05)。结论康复新液联合胸腺肽可以提高老年肺结核患者的疗效和免疫功能,改善肺功能,降低炎症因子水平。Objective To explore the efficacy of kangfuxin liquid combined with thymosin in treatment of pulmonary tuberculosis and investigate its effect on immune function in elderly patients.Methods A total of 117 elderly patients with pulmonary tuberculosis treated in the First Affiliated Hospital of Xinxiang Medical College from January 2020 to February 2023 were retrospectively selected and divided into an observation group of 62 cases and a control group of 55 cases according to the treatment methods.The patients in the control group received kangfuxin liquid treatment,and those in the observation group received treatment with kangfuxin liquid combined with thymosin for 6 months.The curative effect,immune function,lung function and changes in inflammatory factors were compared between the two groups.Results After 6 months of treatment,the total effective rate of the observation group was 83.87%(52/62),which was higher than 64.15%(34/55)of the control(χ^(2)=5.892,P<0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),FEV1/FVC,PEF,FVC,and IFN-γin both groups were increased while those of CD8^(+),CRP and IL-6 decreased as compared with those before treatment(all P<0.05).The levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),forced expiratory volume in 1 second(FEV1)/forced vital capacity(FVC),peak forced expiratory flow(PEF),FVC,interferon gamma(IFN-γ)were significantly higher in the observation group than in the control((66.76±3.22)%vs(64.03±3.15)%,(34.02±3.47)%vs(30.02±3.25)%,(1.27±0.29)%vs(1.14±0.22)%,(84.64±10.67)%vs(75.44±10.13)%,(81.28±13.66)pg·mL^(-1) vs(70.13±11.85)pg·mL^(-1),(3.51±0.68)L vs(2.67±0.62)L,(35.59±3.10)ng·L^(-1) vs(28.43±3.56)ng·L^(-1))(t=4.624,6.411,2.705,4.767,4.687,6.950,11.629,all P<0.05).However,the levels of CD8^(+),CRP and IL-6 were lower in the observation group than in the control((27.67±2.78)%vs(31.18±3.08)%,(11.47±2.31)mg·L^(-1) vs(16.16±2.45)mg·L^(-1),(23.67±2.35)pg·mL^(-1) vs(29.13±2.44)pg·mL^(-1))(t=6.479,10.653,12.319,all P<0.05).Conclusion Kangfuxi

关 键 词：康复新液 胸腺肽 肺结核 疗效 肺功能 免疫功能 炎症因子 

分 类 号：R521[医药卫生—内科学]